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Purpose: To identify the disease-causing mutations in three consanguineous Pakistani families with multiple members
affected by primary congenital glaucoma.
Methods: Blood samples were collected, and DNA was extracted. Linkage analysis for reported primary congenital
glaucoma loci was performed using closely spaced polymorphic microsatellite markers on genomic DNA from affected
and  unaffected  family  members.  All  coding  exons,  the  exon-intron  boundaries,  and  the  5′  untranslated  region  of
CYP1B1 were sequenced.
Results: The alleles of chromosome 2p markers segregate with the disease phenotype in all three families with positive
LOD scores. The sequencing results identified three novel mutations (L177R, L487P, and D374E) and one previously
reported mutation (E229K) in CYP1B1 that segregate with the disease phenotype in their respective families. None of
these sequence variations were present in 96 ethnically matched control samples.
Conclusions: These results strongly suggest that missense mutations in CYP1B1 are most likely to be responsible for
primary congenital glaucoma in these families.
Glaucoma is the second leading cause of visual loss and
accounts  for  approximately  15%  cases  of  blindness
worldwide [1]. It is estimated to affect 60 million people by
2010 and predicted to rise to 80 million by 2020 [2]. Glaucoma
is a group of poorly understood neurodegenerative disorders
that are usually associated with elevated intraocular pressure
[2]. It is clinically characterized by the degeneration of the
optic nerve, loss of retinal ganglion cells, and characteristic
changes in the visual field, which all lead to irreversible vision
loss [3]. Although there has been much progress in finding
new genes and detecting disease-related mutations, little is
known about the function of the mutated gene products and
the  underlying  pathogenic  mechanisms.  Further,  it  is
estimated that all the known loci/genes of glaucoma account
for a minority of all cases of glaucoma, and hence, many
glaucoma genes remain to be identified.
Primary  congenital  glaucoma  (PCG)  is  an  inherited
ocular congenital anomaly of the trabecular meshwork and
anterior chamber angle [4-7]. This leads to the obstruction of
aqueous outflow and increased intraocular pressure (IOP),
which results in optic nerve damage leading to blindness. The
disease manifests in the neonatal or early infantile period with
symptoms of photophobia, epiphora, signs of enlargement of
the globe, edema, opacification of the cornea, and breaks in
the Descemet's membrane. The mode of inheritance is largely
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autosomal recessive with variable penetrance, but rare cases
of pseudo dominance are also seen in families with multiple
consanguinity  [8-11].  Three  chromosomal  loci  have  been
linked  to  PCG,  GLC3A  (2p21;  OMIM  231300),  GLC3B
(1p36; OMIM 600975), and GLC3C (14q24.3) [12,13]. To
date, only mutations in the human cytochrome P450 gene,
CYP1B1 (OMIM 601771), have been reported to cause PCG.
Here, we report three consanguineous Pakistani families
diagnosed  with  early  onset  primary  congenital  glaucoma.
Linkage analysis with chromosome 2p21 markers that were
harboring  CYP1B1  provided  positive  LOD  scores.
Sequencing  of  CYP1B1  identifies  three  novel  mutations
(L177R, L487P, and D374E) and one previously reported
mutation (E229K) that segregated with the disease phenotype
in their respective families. None of these sequence variations
were present in 96 ethnically matched control samples.
METHODS
Thirteen consanguineous Pakistani families with PCG were
recruited to participate in a study to understand the genetic
aspects of glaucoma at the National Centre of Excellence in
Molecular  Biology  (Lahore,  Pakistan).  This  study  was
approved by the internal review board (IRB) of the National
Centre of Excellence in Molecular Biology. The participating
subjects gave informed consent, consistent with the tenets of
the Declaration of Helsinki. All three families described in
this study are from the Punjab province of Pakistan.
A detailed medical history was obtained by interviewing
family members. All of the ophthalmological examinations
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2002including slit lamp biomicroscopy and applanation tonometry
were  completed  at  Layton  Rahmatullah  Benevolent  Trust
(LRBT) hospital (Lahore, Pakistan). Diagnosis of PCG was
based on established criteria that include measurement of IOP,
measurement of corneal diameters, observation of optic nerve
head  where  possible,  and  symptoms  of  corneal  edema
including  photophobia,  buphthalmos,  cloudy  cornea,  and
excessive tearing. Patients with elevated IOP associated with
other systemic or ocular abnormalities were excluded. Blood
samples were collected from affected and unaffected family
members.  DNA  was  extracted  by  a  nonorganic  method
described by Grimberg et al. [14]
Genotype analysis: Genotype analysis was performed
with 12 highly polymorphic fluorescent markers for GLC3A,
GLC3B,  and  GLC3C  loci.  Briefly,  each  reaction  was
performed in 5ml reaction mixture containing 40 ng genomic
DNA, 1X PCR Buffer, 1mM dNTP mix, 2.5 mM MgCl2, and
0.2  U  Taq  DNA  polymerase  (Ampli  Taq  Gold  Enzyme;
Applied Biosystems, Foster City, CA). Amplification was
performed  in  a  GeneAmp  PCR  System  9700  (Applied
Biosystems). Initial denaturation was performed for 5 min at
95 °C followed by 10 cycles of 15 s at 94 °C, 15 s at 55 °C,
and 30 s at 72 °C and then 20 cycles of 15 s at 89 °C, 15 s at
55 °C, and 30 s at 72 °C. The final extension was performed
for  10  min  at  72  °C  followed  by  a  final  hold  at  4  °C.
Polymerase chain reaction (PCR) products from each DNA
sample were pooled and mixed with loading cocktail HD-400
containing size standards (Applied Biosystems). The resulting
PCR products were separated in an ABI 3100 DNA Analyzer
and  analyzed  by  using  GeneMapper  software  packages
(Applied Biosystems).
Linkage  analysis:  Two-point  linkage  analysis  was
performed using the FASTLINK version of MLINK from the
LINKAGE program package [15,16]. All linkage packages
are provided in the public domain by the Human Genome
Mapping  Project  Resources  Centre  (Cambridge,  UK).
Maximum  LOD  scores  were  calculated  using  ILINK.
Autosomal recessive PCG was analyzed as a fully penetrant
trait with an affected allele frequency of 0.001. The marker
order and distances between the markers were obtained from
the  Marshfield  database  and  the  National  Center  for
Biotechnology Information (NCBI) chromosome 2 sequence
maps. Allele frequencies were estimated from 100 unrelated
and  unaffected  individuals  from  the  Punjab  province  of
Pakistan.
Mutation screening: Primer pairs for individual exons of
CYP1B1  were  designed  using  the  Primer3  program.  The
primers are listed in Table 1. Amplifications were performed
in a 25 μl reaction containing 50 ng of genomic DNA, 2.5 μl
1X PCR buffer, 8 pmoles of each primer, 2.5 mM dNTP, 2.5
 mM  MgCl2,  and  0.2  U  Taq  DNA  polymerase  (Applied
Biosystems). Amplification  was  performed  in  a  GeneAmp
PCR System 9700 (Applied Biosystems). PCR amplification
consisted of a denaturation step at 96 °C for 5 min, followed
by 40 cycles, each at 96 °C for 45 s followed by 57 °C for 45
s and 72 °C for 1 min. PCR products were analyzed on 2%
agarose gel and purified by ethanol precipitation. The PCR
primers for each exon were used for bidirectional sequencing
using  Big  Dye  Terminator  Ready  reaction  mix  (Applied
Biosystems)  according  to  the  manufacturer’s  instructions.
Sequencing products were precipitated, resuspended in 10 μl
of formamide, and denatured at 95 °C for 5 min. Sequencing
was  performed  on  an  ABI  3100  Automated  sequencer
(Applied Biosystems). Sequencing results were assembled
using the ABI PRISM sequencing analysis software version
3.7 and analyzed using Chromas software version 1.45.
RESULTS
All three families reported here, PKGL021, PKGL022, and
PKGL026,  are  from  the  Punjab  province  of  Pakistan.  A
detailed medical history was obtained by interviewing family
members. Ophthalmological examinations were completed at
the LRBT hospital in Lahore, Pakistan. The symptoms of
glaucoma in affected individuals in family PKGL021 were
present at birth. Visual acuity is confined to hand motion or
light perception. The IOP is controlled with antiglaucoma
treatments.  Similarly,  glaucoma  in  affected  individuals  of
family PKGL022 was diagnosed within the first month after
birth. Clinical features include bilateral buphthalmos eyes,
corneal opacity, and central corneal haze. Visual acuity was
TABLE 1. THE PRIMER SEQUENCES AND ANNEALING TEMPERATURES FOR CYP1B1.
Exon Forward Primer Reverse Primer Annealing Temp
(°C)
1 GCTCCCATGAAAGCCTGCTG ACGCCACCCGCTACCTGTAA 63
2a GGCCATTTCTCCAGAGAGTC GAACTCTTCGTTGTGGCTGA 57
2b ATGATGCGCAACTTCTTCAC CACTGTGAGTCCCTTTACCG 57
3a AGCCTATTTAAGAAAAAGTGGAA AATTGAGAAGCAGCACAAAA 54
3b ATAAGAAGCAAGAGGCAAGC AGGTACAACATCACCTTGGAG 55
3c CAGTTGCTCAAAAAGAAATCA AAAGAACATCCAGGTAATTCA 55
3d TGAACATTCTCCTGTGGAAG ATTCCAAACCACAAAACAGA 54
3e TTTGGAGCACAAAATTCAAA AGCTTTGACATACAAATGAAGC 55
3f TGCTGACAACCATTAAAGTCA AAATGTAACCTCCGTGTTGG 55
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2003reduced  to  counting  fingers.  The  IOP  of  both  affected
individuals of PKGL022 was considerably higher than the
affected individuals of PKGL021 and PKGL026. The clinical
records indicate that individual 11 and 12 have 43/50 (OD/
OS), and 23/37 (OD/OS) mm Hg of intraocular pressure,
respectively.  Lastly,  ophthalmic  examinations  of  affected
individuals of PKGL026 show typical features of glaucoma
with  elevated  IOP  and  visual  acuity  reduced  to  counting
fingers or light perception. The symptoms of glaucoma were
either present at birth or appeared in the first six weeks after
birth.
Two-point  linkage  analysis  with  chromosome  2p21
markers provided positive LOD scores. For PKGL021, the
maximum LOD scores of 1.43, 1.47, and 0.91 were obtained
with  markers  D2S352,  D2S1346,  and  D2S2331  at  θ=0,
respectively (Table 2). Similarly, for PKGL022, maximum
Figure 1. Family pedigrees. Pedigrees of A) PKGL021, B) PKGL022 and C) PKGL026. Squares denote males while circles denote females.
Filled symbols indicate affected individuals. A double line between individuals signifies consanguinity, and a diagonal line through a symbol
indicates a deceased family member. The haplotypes of six adjacent chromosome 2p21 microsatellite markers are shown with alleles forming
the risk haplotype shaded black, alleles cosegregating with PCG but not showing homozygosity shaded gray, and alleles not cosegregating
with PCG shown in white.
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2004LOD scores of 1.65, 1.35, 1.48, and 1.60 were obtained with
markers D2S2163, D2S177, D2S1346, and D2S2331 at θ=0,
respectively (Table 2). Lastly, for PKGL026, maximum LOD
scores  of  5.16,  4.86,  3.71,  and  2.96  were  obtained  with
markers D2S2163, D2S177, D2S1346, and D2S2331 at θ=0,
respectively (Table 2). Haplotype analysis show that all the
affected individuals of PKGL021, PKGL022, and PKGL026
have homozygous alleles for D2S2163, D2S177, D2S1346,
and D2S2331 short tandem repeat (STR) markers whereas the
normal individuals are either heterozygous carriers of the
disease allele or are homozygous for the normal allele (Figure
1).
All  coding  exons,  exon-intron  boundaries,  and  the  5′
untranslated region of CYP1B1 were sequenced in all three
families. In PKGL021, a C→G transversion in exon 3, c.
1122C>G,  was  identified  resulting  in  an  aspartic  acid  to
Figure  2.  Sequence  chromatograms.
The  forward  and  reverse  sequence
chromatograms  of  (A)  unaffected
individual  9  of  PKGL021,  (B)
individual 5 of PKGL021, heterozygous
and  (C)  individual  7  of  PKGL021,
homozygous for a C→G transversion in
exon  3,  c.1122C>G,  resulting  in  a;
p.D374E, (D) individual 8 of PKGL022,
heterozygous and (E) individual 10 of
PKGL022,  homozygous  for  G→A
transition  in  exon2,  c.685G>A,
resulting  in  mutation  p.E229K,  (F)
individual 8 of PKGL022, heterozygous
and  (G)  individual  10  of  PKGL022,
homozygous for a T→C transition in
exon  3:  c.1460T>C  resulting  in  a;
p.L487P (H) unaffected individual 21 of
PKGL026,  (I)  individual  7  of
PKGL026,  heterozygous,  and  (J)
individual  16  of  PKGL026,
homozygous for a T→G transversion in
exon  2:  c.530T>G:  resulting  in  p.
L177R.
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2005glutamic acid change, D374E (Figure 2). In PKGL022, a
G→A transition in exon 2, c.685G>A, was identified resulting
in  a  glutamic  acid  to  lysine  change,  E229K  (Figure  2).
Additionally, in PKGL022, a T→C transition in exon 3, c.
1460T>G,  was  identified  leading  to  a  leucine  to  proline
change, p. L487P (Figure 2). Both these mutations segregated
with  the  disease  phenotype  in  PKGL022.  Finally,  in
PKGL026, a T→G transversion in exon 2, c.530T>G, was
identified leading to a leucine to arginine change, L177R
(Figure  2).  All  the  above  mentioned  variations  were
homozygous and segregated with the disease phenotype in
their respective families. None of these sequence variations
were present in 96 ethnically matched control samples. Six
single  nucleotide  polymorphisms  (SNPs)  including
rs2617266, a SNP residing 12 bp upstream of the first coding
exon  of  CYP1B1,  rs10012,  rs1056827,  rs1056836,
rs1056837, and rs1800440 were examined to construct the
disease  haplotype.  As  shown  in  Table  3,  the  affected
individuals of PKGL021 and PKGL022 harbor T-G-T-C-C-
A  haplotype  whereas  PKGL026  has  a  C-C-G-G-T-A
haplotype.
DISCUSSION
Here,  we  report  three  consanguineous  Pakistani  families
diagnosed  with  primary  congenital  glaucoma.  Linkage
analysis  with  chromosome  2p21  markers,  which  harbor
CYP1B1,  provided  positive  LOD  scores.  Sequencing  of
CYP1B1 identified three novel mutations (L177R, L487P, and
D374E) and a previously reported mutation (E229K) in these
families. All variations segregated with the disease phenotype
in the respective families, and none of them were present in
96 control samples of similar ethnic population. Amino acids,
Leu177, Asp374, and Leu487, are highly conserved among
higher primate species (Figure 3). Linkage to chromosome
2p21 harboring CYP1B1, segregation of these variations with
the disease phenotype, and the absence of these variations in
96  control  samples  of  similar  ethnic  population  strongly
suggest that these variations are most likely to be responsible
for primary congenital glaucoma in these families.
Figure 3. Sequence alignment of amino acids of CYP1B1 among
higher primate species. The alignment of CYP1B1 among higher
primate species shows the conservation of Asp374 (green), Leu487
(blue), and Leu177 (red).
TABLE 2. TWO-POINT PARAMETRIC LOD SCORES OF PKGL021, PKGL022, AND PKGL026 WITH CHROMOSOME 2p MARKERS.
Marker cM Mb 0.00 0.01 0.03 0.05 0.07 0.09 0.10 0.20 0.30 Zmax θmax
PKGL021
D2S149 34.0 14.31 −4.34 −1.19 −0.74 −0.54 −0.42 −0.33 −0.30 −0.12 −0.06 −0.06 0.30
D2S2150 40.5 20.39 −2.59 −1.27 −0.83 −0.64 −0.52 −0.44 −0.41 −0.23 −0.17 −0.17 0.30
D2S352 50.7 31.34 1.43 1.39 1.33 1.26 1.19 1.12 1.09 0.73 0.39 1.43 0.00
D2S2163 59.4 37.78 0.38 0.37 0.34 0.32 0.29 0.27 0.25 0.14 0.06 0.38 0.00
D2S177 59.4 37.87 0.43 0.42 0.39 0.36 0.33 0.31 0.29 0.17 0.07 0.43 0.00
D2S1346 59.4 38.11 1.47 1.44 1.37 1.3 1.24 1.17 1.13 0.79 0.46 1.47 0.00
D2S2331 59.9 38.79 0.91 0.89 0.82 0.77 0.71 0.65 0.62 0.34 0.09 0.91 0.00
D2S391 70.3 46.25 −2.89 −1.27 −0.82 −0.61 −0.48 −0.39 −0.35 −0.13 −0.05 −0.05 0.30
D2S337 80.7 61.51 −2.89 −1.27 −0.82 −0.61 −0.48 −0.39 −0.35 −0.13 −0.05 −0.05 0.30
PKGL022
D2S149 34.0 14.31 0.16 0.14 0.13 0.12 0.12 0.11 0.11 0.09 0.04 0.16 0.00
D2S2150 40.5 20.39 0.48 0.46 0.43 0.40 0.37 0.34 0.32 0.18 0.08 0.48 0.00
D2S352 50.7 31.34 0.16 0.14 0.13 0.12 0.12 0.11 0.11 0.09 0.04 0.16 0.00
D2S2163 59.4 37.78 1.65 1.61 1.52 1.43 1.35 1.26 1.22 0.79 0.40 1.65 0.00
D2S177 59.4 37.87 1.35 1.31 1.23 1.16 1.08 1.01 0.97 0.61 0.30 1.35 0.00
D2S1346 59.4 38.11 1.48 1.44 1.36 1.28 1.20 1.12 1.08 0.69 0.34 1.48 0.00
D2S2331 59.9 38.79 1.60 1.56 1.48 1.39 1.31 1.22 1.18 0.76 0.38 1.60 0.00
D2S391 70.3 46.25 −3.92 −1.49 −0.98 −0.73 −0.57 −0.45 −0.40 −0.13 −0.04 −0.04 0.30
D2S337 80.7 61.51 −3.08 −1.03 −0.59 −0.39 −0.28 −0.20 −0.17 −0.02 0.01 0.01 0.30
PKGL026
D2S149 34.0 14.31 -∞ −2.82 −1.08 −0.36 0.05 0.32 0.41 0.76 0.62 0.76 0.20
D2S2150 40.5 20.39 -∞ −4.62 −2.80 −2.00 −1.50 −1.14 −1.00 −0.22 0.05 0.05 0.30
D2S352 50.7 31.34 -∞ −1.55 −0.68 −0.31 −0.10 0.04 0.10 0.30 0.25 0.30 0.20
D2S2163 59.4 37.78 5.16 5.06 4.86 4.66 4.45 4.24 4.14 3.06 1.97 5.16 0.00
D2S177 59.4 37.87 4.86 4.76 4.56 4.36 4.16 3.96 3.86 2.83 1.79 4.86 0.00
D2S1346 59.4 38.11 3.71 3.71 3.65 3.56 3.44 3.3 3.23 2.42 1.56 3.71 0.00
D2S2331 59.9 38.79 2.96 2.92 2.82 2.71 2.59 2.47 2.41 1.77 1.15 2.96 0.00
D2S391 70.3 46.25 1.60 1.57 1.49 1.41 1.33 1.25 1.21 0.81 0.45 1.60 0.00
D2S337 80.7 61.51 -∞ 1.52 1.85 1.92 1.92 1.87 1.84 1.35 0.73 1.92 0.05
LOD  scores  were  calculated  at  different  θ values  for  each  marker  with  the  FASTLINK  version  of  MLINK  from  the
LINKAGE program package. Maximum LOD scores for each marker were calculated using ILINK.
Molecular Vision 2008; 14:2002-2009 <http://www.molvis.org/molvis/v14/a236> © 2008 Molecular Vision
2006CYP1B1 is a member of the CYP450 super family, which
contains 58 functional genes in the human genome [2]. The
gene product is a 543 amino acid protein that contains the
NH2-terminal membranous region; a 10 residue long, proline-
rich region; and a cytosolic globular domain [2]. Mutations in
CYP1B1 are the predominant cause of PCG in patients from
various ethnic backgrounds. Previous studies have shown that
missense mutations in CYP1B1 affect highly conserved and
functionally  important  regions  of  CYP1B1,  resulting  in
significant structural changes and reduced CYP1B1 activity
[11,17-21].
In  PKGL021,  we  identified  a  homozygous  missense
change  that  substitutes  aspartic  acid  at  position  374  with
glutamic acid in affected individuals. Previously, aspartic acid
to  asparagine  substitution  at  the  same  position  has  been
reported to lead to PCG phenotype in Saudi Arabian patients
[22]. Amino acid 374 maps to helix K, one of the highly
conserved core structures thought to be involved in correct
folding and heme binding of the cytochrome P450 molecule
[23]. Further mutations that map to helix K are reported to be
responsible for the severe PCG phenotype in Indian patients
[21].
In PKGL022, a leucine to proline substitution at residue
487 and a previously reported mutation, E229K, segregated
in an autosomal recessive pattern with the disease phenotype.
L487P affects the highly conserved position marking the end
of helix L, and the proline substitution at this position could
potentially disrupt the helical structure and possibly affect the
native  three-dimensional  structures.  Conversely,  glutamic
acid 229 resides in the vicinity of the substrate-binding region
(SBR) and is reported to cause conformational changes in
CYP1B1 [24]. Heterozygous carriers of this mutation develop
PCG and primary open-angle glaucoma phenotype [25-32].
Interestingly, compound heterozygous carriers of E229K and
L487P in PKGL022 show no symptoms of PCG. Noteworthy,
the  affected  individuals  of  PKGL022  have  higher  IOP
compared  with  affected  individuals  examined  during  this
study. Mutation L177R was detected in PKGL026. Amino
acid  177  in  CYP1B1  resides  in  a  highly  conserved  NH2-
capping region [21]. The non-conservative replacement of a
non-polar  amino  acid,  leucine,  with  positively  charged
arginine is most likely to impair the native protein structure
and consequently affect the protein function.
SNPs,  especially  rs2617266,  rs10012,  rs1056827,
rs1056836, rs1056837, and rs1800440, have been used to
construct  haplotypes  of  CYP1B1  mutations  [18,33,34].
According to the proposed hypothesis of evolution, the T-G-
T-C-C-A and C-C-G-G-T-A haplotypes are ancestral human
haplotypes  whereas  the  T-G-T-C-C-A  haplotype  is
comparatively recent [35,36]. To date, approximately 50% of
known CYP1B1 mutations are associated with the C-C-G-G-
T-A haplotype while the T-G-T-C-C-A and C-C-G-C-C-G
haplotypes are less frequent and are associated with 9.7% and
7% of CYP1B1 mutations, respectively [31,33,37]. Affected
individuals of PKGL021 and PKGL022 harbor a T-G-T-C-C-
A haplotype, which is indicative of their common ancestry.
Noteworthy, the previously reported mutation, E229K, which
segregates in PKGL022, has been associated with the T-G-T-
C-C-A  haplotype  in  French,  German,  Indian,  and  Iranian
patients [35,36]. The D374N mutation found in Saudi Arabian
patients  is  associated  with  the  C-C-G-G-T-A  haplotype,
which is in contrast to the T-G-T-C-C-A haplotype coupled
with D374E mutation in PKGL021 [38]. Finally, the L177R
mutation detected in PKGL026 is present in the C-C-G-G-T-
A haplotype, which is frequently associated with CYP1B1
mutations.
Studies of pathogenic sequence variants in CYP1B1 will
contribute  to  better  understanding  of  primary  congenital
glaucoma.  Identification  of  these  mutations  reaffirms  the
diverse allelic heterogeneity of CYP1B1 in the pathogenesis
of  PCG.  This  will  further  help  in  the  elucidation  of  the
structure-function relationship of CYP1B1 and hence, lead to
the  development  of  novel  therapeutic  approaches.
Consequently,  the  association  of  specific  haplotypes  with
pathogenic mutations will contribute to our knowledge of
haplotype  clustering  of  PCG  associated  with  CYP1B1
mutations. This will overall enhance our understanding of
primary congenital glaucoma at the molecular level.
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